Meeting
2022 ASCO Annual Meeting
DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues.
Authors
Hongcang Gu
Zhejiang ShengTing Biotech Co. Ltd/Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China
Hongcang Gu , Shirong Zhang , Shutao He , Xin Zhu , Yunfei Wang , Qionghuan Xie , Wenxian Wang , Shenglin Ma , Jiantao Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3079)
DOI
10.1200/JCO.2022.40.16_suppl.3079
Abstract #
3079
Poster Bd #
71
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A second generation microRNA-based assay for diagnosing tumor tissue origin.
First Author: R. T. Aharonov
Poster
2024 ASCO Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of squamous cell carcinoma of unknown primary (SCCUP) presenting with inguinal, pelvic, and retroperitoneal (I/P/RP) metastases.
First Author: Stephanie Lakritz
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comprehensive genomic profiling of squamous cell carcinoma of unknown primary presenting with liver metastases.
First Author: Hannah Ruth Robinson
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study.
First Author: Pascal Hammel